1. Home
  2. TNGX vs BEAG Comparison

TNGX vs BEAG Comparison

Compare TNGX & BEAG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • TNGX
  • BEAG
  • Stock Information
  • Founded
  • TNGX 2014
  • BEAG 2021
  • Country
  • TNGX United States
  • BEAG United States
  • Employees
  • TNGX N/A
  • BEAG N/A
  • Industry
  • TNGX Biotechnology: Pharmaceutical Preparations
  • BEAG
  • Sector
  • TNGX Health Care
  • BEAG
  • Exchange
  • TNGX Nasdaq
  • BEAG NYSE
  • Market Cap
  • TNGX 351.2M
  • BEAG 326.6M
  • IPO Year
  • TNGX N/A
  • BEAG 2024
  • Fundamental
  • Price
  • TNGX $5.63
  • BEAG $10.45
  • Analyst Decision
  • TNGX Strong Buy
  • BEAG
  • Analyst Count
  • TNGX 6
  • BEAG 0
  • Target Price
  • TNGX $12.20
  • BEAG N/A
  • AVG Volume (30 Days)
  • TNGX 3.4M
  • BEAG 215.7K
  • Earning Date
  • TNGX 08-06-2025
  • BEAG 01-01-0001
  • Dividend Yield
  • TNGX N/A
  • BEAG N/A
  • EPS Growth
  • TNGX N/A
  • BEAG 221.31
  • EPS
  • TNGX N/A
  • BEAG 0.28
  • Revenue
  • TNGX $40,990,000.00
  • BEAG N/A
  • Revenue This Year
  • TNGX N/A
  • BEAG N/A
  • Revenue Next Year
  • TNGX N/A
  • BEAG N/A
  • P/E Ratio
  • TNGX N/A
  • BEAG $37.29
  • Revenue Growth
  • TNGX 10.09
  • BEAG N/A
  • 52 Week Low
  • TNGX $1.03
  • BEAG $9.84
  • 52 Week High
  • TNGX $12.02
  • BEAG $11.20
  • Technical
  • Relative Strength Index (RSI)
  • TNGX 77.32
  • BEAG N/A
  • Support Level
  • TNGX $4.80
  • BEAG N/A
  • Resistance Level
  • TNGX $5.63
  • BEAG N/A
  • Average True Range (ATR)
  • TNGX 0.52
  • BEAG 0.00
  • MACD
  • TNGX -0.03
  • BEAG 0.00
  • Stochastic Oscillator
  • TNGX 83.33
  • BEAG 0.00

About TNGX Tango Therapeutics Inc.

Tango Therapeutics Inc is a biotechnology company. It is dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. It is currently developing two MTA-cooperative PRMT5 inhibitors; TNG462 for non-CNS cancers, including pancreatic and lung cancer, and TNG456, a next-generation, brain-penetrant PRMT5 inhibitor, for CNS cancers, including GBM. Its pipeline products are PRMT5 and CoREST.

About BEAG BOLD EAGLE ACQUISITION CORP

Bold Eagle Acquisition Corp is a blank check company.

Share on Social Networks: